SGRY
Surgery Partners Inc
$
22.550
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
22.550
Open
22.470
VWAP
--
Vol
92.37K
Mkt Cap
2.88B
Low
22.270
Amount
--
EV/EBITDA(TTM)
12.54
Total Shares
127.09M
EV
8.04B
EV/OCF(TTM)
30.31
P/S(TTM)
0.89
Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility Services segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of 161 surgical facilities comprised of 142 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 200 locations in 31 states, including short-stay surgical hospitals.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
948.40M
+9.72%
0.452
+2.82%
838.47M
+8.84%
0.213
+12.22%
816.96M
+7.2%
0.135
-35.67%
Estimates Revision
The market is revising Downward the revenue expectations for Surgery Partners, Inc. (SGRY) for FY2025, with the revenue forecasts being adjusted by -0.3% over the past three months. During the same period, the stock price has changed by 0.99%.
Revenue Estimates for FY2025
Revise Downward
-0.3%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-20.82%
In Past 3 Month
Stock Price
Go Up
+0.99%
In Past 3 Month
10 Analyst Rating
38.45% Upside
Wall Street analysts forecast SGRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGRY is 31.22 USD with a low forecast of 24.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
3 Hold
0 Sell
Moderate Buy
38.45% Upside
Current: 22.550
Low
24.00
Averages
31.22
High
36.00
38.45% Upside
Current: 22.550
Low
24.00
Averages
31.22
High
36.00
BofA
Neutral -> Buy
upgrade
$28
2025-07-28
New
Reason
BofA
Price Target
$28
2025-07-28
New
upgrade
Neutral -> Buy
Reason
BofA upgraded Surgery Partners to Buy from Neutral with a $28 price target.
BofA
No Rating
to
Buy
upgrade
$28
2025-07-28
New
Reason
BofA
Price Target
$28
2025-07-28
New
upgrade
No Rating
to
Buy
Reason
BofA changed the firm's rating on Surgery Partners to Buy from No Rating with a $28 price target as the firm no longer believes that the stock is trading on deal speculation following June's report that Surgery rejected a buyout offer from Bain Capital. Noting that the stock is trading at a depressed multiple, the firm cites the strong tailwinds it sees for Ambulatory Surgery Centers for its Buy rating.
TD Cowen
TD Cowen
maintain
$NULL
2025-07-16
Reason
TD Cowen
TD Cowen
Price Target
$NULL
2025-07-16
maintain
Reason
TD Cowen analysts say the rate updates of the Centers for Medicare and Medicaid Services' proposed rule for hospital outpatient and ambulatory surgery center procedures will be overshadowed by a proposal to eliminate the inpatient only list, which is positive for Surgery Partners (SGRY) and United Surgical Partners (USPI), and the 340B remedy reduction higher from 0.5% to 2.0% per year, which is likely negative for HCA Healthcare (HCA), Tenet Healthcare (THC) and Universal Health (UHS). However, the firm expects this to be lobbied by the American Hospital Association and awaits additional commentary from the industry. The rule projects an overall 2.4% rate update for outpatient hospital and ambulatory surgery center procedures, the analysts tell investors in a research note. Shares of HCA are down 3% to $359.09 in morning trading while Surgery Partners is up 2% to $22.38.
Barclays
Andrew Mok
Equal Weight
downgrade
$25 -> $24
2025-05-27
Reason
Barclays
Andrew Mok
Price Target
$25 -> $24
2025-05-27
downgrade
Equal Weight
Reason
Barclays analyst Andrew Mok lowered the firm's price target on Surgery Partners to $24 from $25 and keeps an Equal Weight rating on the shares. The company's Q1 results continued to display resilient demand trends and success in physician recruitment, but these were offset by decelerating pricing and accelerating unit cost trends, the analyst tells investors in a research note.
Benchmark
Bill Sutherland
Strong Buy
Reiterates
$35
2025-04-21
Reason
Benchmark
Bill Sutherland
Price Target
$35
2025-04-21
Reiterates
Strong Buy
Reason
RBC Capital
Ben Hendrix
Buy
Reiterates
$35
2025-03-25
Reason
RBC Capital
Ben Hendrix
Price Target
$35
2025-03-25
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Surgery Partners Inc (SGRY.O) is 24.56, compared to its 5-year average forward P/E of -334.41. For a more detailed relative valuation and DCF analysis to assess Surgery Partners Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-334.41
Current PE
24.56
Overvalued PE
1279.03
Undervalued PE
-1947.84
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
18.34
Current EV/EBITDA
14.32
Overvalued EV/EBITDA
21.71
Undervalued EV/EBITDA
14.97
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
1.23
Current PS
0.78
Overvalued PS
1.64
Undervalued PS
0.81
Financials
Annual
Quarterly
FY2025Q1
YoY :
+8.17%
776.00M
Total Revenue
FY2025Q1
YoY :
+1.21%
91.80M
Operating Profit
FY2025Q1
YoY :
-101.23%
-300.00K
Net Income after Tax
FY2025Q1
YoY :
+200.00%
-0.30
EPS - Diluted
FY2025Q1
YoY :
-184.77%
-16.70M
Free Cash Flow
FY2025Q1
YoY :
-4.48%
16.19
Gross Profit Margin - %
FY2025Q1
YoY :
-12.50%
5.46
FCF Margin - %
FY2025Q1
YoY :
-101.18%
-0.04
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
487.0K
USD
6
6-9
Months
3.0M
USD
7
0-12
Months
196.7K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 682.35% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
625.6K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
3.3M
Volume
Months
6-9
1
425.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
487.0K
USD
6
6-9
Months
3.0M
USD
7
0-12
Months
196.7K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SGRY News & Events
Events Timeline
2025-06-17 (ET)
2025-06-17
08:03:17
Surgery Partners reaffirms FY25 revenue view $3.3B-$3.45B, consensus $3.38B
2025-06-17
08:02:18
Surgery Partners, Bain Capital conclude discussions
2025-05-12 (ET)
2025-05-12
07:33:06
Surgery Partners reaffirms FY25 revenue view $3.3B-$3.45B, consensus $3.39B
Sign Up For More Events
Sign Up For More Events
News
9.5
07-22NASDAQ.COMDanaher (DHR) Q2 Earnings and Revenues Top Estimates
9.5
07-18NewsfilterSurgery Partners, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call Details
2.0
06-17NASDAQ.COMRSI Alert: Surgery Partners (SGRY) Now Oversold
Sign Up For More News
People Also Watch
AIN
Albany International Corp
72.210
USD
-0.17%
RNW
Renew Energy Global PLC
7.610
USD
-0.52%
CXW
CoreCivic Inc
20.190
USD
+0.35%
MRCY
Mercury Systems Inc
52.320
USD
-0.83%
AMRX
Amneal Pharmaceuticals Inc
8.215
USD
+0.55%
ENR
Energizer Holdings Inc
23.400
USD
-1.22%
ELP
Companhia Paranaense de Energia
8.380
USD
+0.48%
ODD
Oddity Tech Ltd
69.555
USD
+1.64%
KLIC
Kulicke and Soffa Industries Inc
35.450
USD
+0.62%
RXRX
Recursion Pharmaceuticals Inc
6.050
USD
-4.12%
FAQ
What is Surgery Partners Inc (SGRY) stock price today?
The current price of SGRY is 22.55 USD — it has increased 0.49 % in the last trading day.
What is Surgery Partners Inc (SGRY)'s business?
What is the price predicton of SGRY Stock?
What is Surgery Partners Inc (SGRY)'s revenue for the last quarter?
What is Surgery Partners Inc (SGRY)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Surgery Partners Inc (SGRY)'s fundamentals?
How many employees does Surgery Partners Inc (SGRY). have?